CN112174967A - Alkoxy substituted Latricinib compound and preparation method and application thereof - Google Patents

Abstract

The invention relates to an alkoxy substituted Latricinib compound and a preparation method and application thereof, wherein the alkoxy substituted Latricinib compound comprises Latricinib marked by radioactive atoms or non-radioactive atoms, wherein the radioactive atoms comprise 11C, 3H and 18F, and the non-radioactive atoms comprise 12C, 2H and 19F. Compared with the prior art, the alkoxy Latrotinib analogue is a novel TRK PET probe, has TRK specificity, and has the advantages of realizing the visualization and quantitative evaluation of the physiological and biochemical functions and the pharmacological process of the drug molecule at the molecular level in vivo by means of a PET (Positron emission tomogry) non-immersion imaging technology.

Description

Alkoxy substituted Latricinib compound and preparation method and application thereof

Technical Field

The invention relates to the field of chemical drug synthesis, in particular to an alkoxy substituted Latricinib compound and a preparation method and application thereof.

Background

Larotrectinib, also known as ARRY-470 and LOXO-101, is an orally bioavailable, potent, atp-competitive inhibitor of TRKA, TRKB and TRKC. The IC50 values for LOXO-101 in the low nanomolar range inhibit the effects of all three TRK family members in binding and cellular assays 100-fold more selective than other kinases and show acceptable drug properties and safety in non-clinical models. The neurotrophin receptors of the TRK family, TRKA, TRKB, and TRKC (encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively), and their neurotrophin ligands, regulate the growth, differentiation, and survival of neuro.

Larotrectinib is developed by Loxo Oncology company, is used as a broad-spectrum tumor drug and is used for all tumor patients expressing Tropomyosin Receptor Kinase (TRK), the TRK small molecule inhibitor has strong selectivity on TRK, and larotretinib can inhibit the growth of tumors by inhibiting TRK signal channels. larotretinib is a potent oral TRK inhibitor with consistent and persistent antitumor activity in TRK-fused tumors, is suitable for a wide range of patient ages and tumor types, has indications distributed over 13 different tumor types, and has good tolerance, and is effective against a variety of adult and pediatric solid tumors, including salivary gland cancer (salivar), infantile fibrosarcoma carcinoma (infantile fibrosarcoma), lung cancer (lung), thyroid cancer (thyroid), colon cancer (colon), melanoma (melanoma), cholangiocarcinoma (cholangio), gastrointestinal cancer (GIST), breast cancer, and various sarcoma cancers (sarcomas). The FDA (http:// www.chemdrug.com/article/11/) in the United states has granted the larotretinib orphan drug qualification and breakthrough drug qualification. Larotrectinib is expected to be the first therapeutic drug to be developed and approved simultaneously in adults and children, and is the first tumor-targeting therapeutic drug in a molecular sense spanning all traditionally defined tumor types. The structure of Larotrectinib is shown as follows:

for all tumor patients expressing Tropomyosin Receptor Kinase (TRK), Larotrecini, a small molecule inhibitor, has strong selectivity and strong TRK inhibition on TRK, and tropomyosin receptor kinase (Trk) is a tyrosine kinase receptor, is mainly encoded by NTRK gene and is genetically expressed as gene fusion, and Trk receptors are divided into TrkA (molecular weight 140kD), TrkB (145kD) and TrkC (145kD), tropomyosin is a membrane protein receptor and mainly comprises an extramembranous ligand binding region, a transmembrane region and an intramembranous ATP binding region, the extramembranous junction regions of TrkA, TrkB and TrkC show high similarity, and Trk plays an important role in physiology, development and function of a central nervous system and a peripheral nervous system, and after being combined with the extramembranous ligand, normal Trk receptor forms a dimer and causes phosphorylation of the kinase region and activation, thereby triggering the activation of downstream signaling pathways and further promoting the proliferation and differentiation of cells. NTRK gene rearrangement and fusion are common phenomena in various cancers, are widely existed in various cancers (such as rectal cancer, non-small cell lung cancer, breast cancer, glioma, astrocytoma, infantile fibrosarcoma, thyroid cancer, gastrointestinal stromal tumor and the like), and encode various prokinase Trk fusion proteins. These fusion proteins are capable of activating downstream pathways and promoting tumor formation and cell proliferation in the absence of a ligand. Clinically, when the Larotrectinib small-molecule inhibitor is used, a patient with NTRK gene rearrangement and fusion needs to be screened in advance, so the Trk fusion protein also becomes a drug target and a diagnostic marker of a spectrum in the cancer field. So far, the clinical technical means for detecting NTRK fusion mainly comprise NGS sequencing, FISH and IHC, and no more effective technical means is available at present.

Documents CN109705124A and CN109942582 disclose a radioactive fluorine labeled larotryptinb compound, and a preparation method and an application thereof, which utilize a non-immersion imaging technology, pet (potitron emission tomograph), to realize visualization and quantitative evaluation of physiological and biochemical functions and pharmacological processes of drug molecules at the in vivo molecular level, trace the distribution of larotryptinb molecules in animals or humans and the conditions of solid tumors on line, visually judge the physiological functions and pharmacological processes of larotryptinb in animals, humans and tumors, evaluate the curative effect and the effect after healing thereof, and enhance the concentration effect of larotryptinb in tumors. However, the preparation route of the literature is long, and especially the synthesis of the labeled precursor is complex, so that the clinical application of the fluorine labeled Larotrectinib is hindered.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provide an alkoxy substituted Latricinib compound with simple synthesis and good medicinal effect, a preparation method and application thereof.

The purpose of the invention can be realized by the following technical scheme: an alkoxy-substituted lapatinib compound comprising lapatinib labeled with radioactive atoms or non-radioactive atoms, wherein the radioactive atoms include 11C, 3H, 18F and the non-radioactive atoms include 12C, 2H, 19F. Including but not limited to compounds having the following structural formula:

the invention provides an alkoxy-like compound, which has the following structural general formula:

wherein R is:^11/12CH₃-，C^1/2/3H₃-，C^18/19F^1/2/3H₂-，C^18/19F₂ ^1/2/3H-，(CH₂)_n ^18/19F-、CH₂(CH₂-O-CH₂CH₂)n^18/19F-，CH₂CH^18/19FCH₂OH-, cycloalkyl, or radiolabeled cycloalkyl [ CH₂(CHCH₂CH)CH₂C^18/19F^1/2/3H₂-]。

The invention provides a quasi-radioactivity¹¹The C-methoxy labeled Latrotinib compound has a structural formula comprising:

the invention provides a quasi-radioactivity³The structural formula of the H-methoxy labeled Latrotinib compound comprises:

the invention provides a quasi-radioactivity¹⁸The structural formula of the F-methoxy labeled Latrotinib compound comprises:

the invention provides a compound which is non-radioactive¹H-、²H-、¹⁹An F-labeled Latricinib compound, the structural formula comprises:

the alkoxy substituted Latrotinib compound is prepared by the following steps:

the alkoxy substituted Latrotinib compound is used as a medicine for clinical and preclinical diagnosis and curative effect evaluation of diseases caused by tropomyosin kinase TRK fusion protein.

Compared with the prior art, the invention has the following beneficial effects:

1. the alkoxy Latrotricib analogues of the present invention, wherein the alkoxy group may be isotopically labelled, for example, with a radioactive fluorine atom such as F-18, or a nonradioactive fluorine atom such as F-19, or a radioactive carbon atom such as C-11, or a radioactive hydrogen atom such as H-3, or a nonradioactive hydrogen atom such as H-2. The alkoxy Latrotinib analogue is a novel TRK PET probe, has TRK specificity, and has the functions of realizing the visualization and quantitative evaluation of the physiological and biochemical functions and the pharmacological process of a drug molecule at the molecular level in a living body by means of a PET (Positron emission tomogry) non-immersion imaging technology. The invention modifies the existing small molecular compound aiming at the Trk fusion protein, thereby further forming a molecular probe capable of specifically diagnosing Trk fusion protein expression, serving as a small molecular inhibitor of Tropomyosin Receptor Kinase (TRK), having strong selectivity on TRK, being used as a PET imaging molecule, accurately positioning the Larotrectinib molecule in vivo to evaluate the tumor condition, realizing the on-line tracing of the distribution of the Larotrectinib molecule in animals or human bodies and the condition of solid tumors, intuitively judging the physiological function and pharmacological process of the Larotrectinib in animals, human bodies and tumors, judging the curative effect and the effect after healing, and enhancing the concentration effect of the Larotrectinib in the tumors. Thereby providing reliable molecular typing data for clinically carrying out molecular diagnosis on the characteristics of the tumor and guiding the clinical medication of related Trk fusion protein. Can also be used for in vitro cell receptor and drug molecule screening and evaluation. The method is relative to

2. The invention adopts an active sulfonate methylation method to prepare the alkoxy Latricinib analogue, and the method has simple route and low cost. Documents CN109705124A and CN109942582 disclose a radioactive fluorine labeled Larotrectinib compound, and a preparation method and application thereof, wherein an adamantane substituted auxiliary acid reaction is adopted to prepare a labeled precursor: a spiro high valence iodine (III) substituted hydroxyl protected Larotrectinib analogue relates to hydroxyl protection, preparation of trifluoroacetic acid iodo-complex, preparation of labeled precursor by adamantane substituted auxiliary acid reaction, preparation of isotope labeled product under the action of fluorine labeling reagent, deprotection and other multi-step reactions.

Detailed Description

The following examples are given for the detailed implementation and specific operation of the present invention, but the scope of the present invention is not limited to the following examples.

The alkoxy Latrotinib analogue can be prepared by the following method:

example 1

Radioactivity¹¹C-methoxy labeled Latricinib compound (R, S) -3- (R-S)¹¹CH₃) -synthesis of Larotrectinib:

the labeled precursor (R, S) -Laeotercetinic 6(1.0mg) was dissolved in a V-shaped reaction flask (5mL) containing 400. mu.l of freshly distilled anhydrous tetrahydrofuran, potassium tert-butoxide (1mg) was added to the reaction solution, and the mixture was allowed to stand for 4 minutes after shaking for 10 seconds. Will be radioactive¹¹C]-methyl trifluoromethanesulfonate (,)¹¹C]CH₃OTf) was added dropwise to the reaction mixture under a stream of nitrogen, turned at room temperature for 5 minutes, and after the completion of the turning, the reaction mixture was heated in a 60 ℃ water bath for 2 minutes and then directly injected into semi-preparative HPLC (Phenomenex C)₁₈10x250 mm,10um, 00G-4094-N0 model, philomennex column, usa) and the eluent is acetonitrile: 1M ammonium formate solution (65:35, v/v) at a flow rate of 10 ml/min. Peak at precursor Rt 5-6min, product Rt 9-10min, product collection based on isotopic γ -detector peak position, dilution with 100uL of deionized water, C18-solid phase extraction short column (Waters) enrichment, elution with ethanol (1mL) to give (R, S) -3-, (R, R-y-l, and (R-y-l) in the form of a solid-phase extraction short column (Waters) solution¹¹CH₃) Laeotteptiib (yield 16%, EOS). Detecting part of ethanol solution with analytical HPLC, determining part of ethanol solution with analytical HPLC, and determining specific activity of radioactivity>2000Ci/mmol (EOS) and radiochemical purity>99%, analysis conditions: phenomenex c18,10250mm,10ml, eluent acetonitrile: 1M ammonium formate solution (65:35, v/v), flow rate 2ml/min, product peak out time Rt 6.9min, isotope gamma detector determined peak position. Diluting ethanol solution with normal saline, and preparing into solution containing (R, S) -3- (R, S) -10% ethanol-saline¹¹CH₃) Laeottretinib final 10% ethanol-saline solution (10 mL).

[¹¹C]-methyl trifluoromethanesulfonate (,)¹¹C]CH₃OTf), reference (A simple synthesis of [11C ]]methyl triflate, appl.radial.Isot.43 (1992) 1383-1385) by [11C]Methyl iodide was completed with AgOTf in a 200 ℃ tubular reactor. The precursor (R, S) -Laeotteptiib 6 was purchased commercially or prepared by reference.

Example 2

Control (R, S) -3- (CH)₃) Preparation of-Larotrectinib (Compound 6)

Under nitrogen protection, the labeled precursor (R, S) -Laeotteptiib 6(4.28g, 0.1mol) was dissolved in a flame-dried magnetically stirred reaction flask (50mL) containing freshly distilled anhydrous tetrahydrofuran (35mL), potassium tert-butoxide (1.34mg, 0.12mol) was added to the reaction mixture, and the reaction was stirred at room temperature for 4 minutes. Methyl trifluoromethanesulfonate liquid (1.36mL,1.45g/mL, 0.12mol) was added dropwise to the reaction mixture over a period of 15 minutes, after the dropwise addition, the reaction mixture was heated in a 60 ℃ water bath for 2 hours, and the completion of the reaction of the starting materials was detected by TLC. The reaction mixture was concentrated under reduced pressure, and the residue was extracted with dichloromethane, washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane/ethyl acetate, 50: 1 to 1: 1) to give (R, S) -3- (CH) as a white solid₃) Larotrectinib (Compound 6) (4.08g), 92.3% yield, mp 98.2 ℃.

TLC: Rf (n-hexane/ethyl acetate, 5/3) ═ 0.32.

ESI-MS(m/z)：[442.19，M+]。

(R, S) -3- (R, S) -novel Compound obtained in example 1-2^11/12CH₃) Laeotercitinib as a novel TRK specific PET probe can be used for affinity evaluation of tropomyosin receptor kinase (Trk for short) and tyrosine kinase receptors in vivo and in vitro, and can be used for detecting the surface of TRK fusion protein in tumor tissuesTherefore, reliable diagnosis and molecular phenotype data are provided for clinical examination, and the method can also be used for in vitro cell receptor and drug molecule screening and evaluation.

Example 3

Radioactivity³H-methoxy labeled Latricinib compound (R, S) -3-, [ solution ]³H]-(C³HH₂) -synthesis of Larotrectinib:

under nitrogen protection, the labeled precursor (R, S) -Laeotteptiib 6(4.28g, 0.1mol) was dissolved in a flame-dried magnetically stirred reaction flask (50mL) containing freshly distilled anhydrous tetrahydrofuran (35mL), potassium tert-butoxide (1.34mg, 0.12mol) was added to the reaction mixture, and the reaction was stirred at room temperature for 4 minutes. Methyl trifluoromethanesulfonate liquid (1.36mL,1.45g/mL, 0.12mol) was added dropwise to the reaction mixture over a period of 15 minutes, after the dropwise addition, the reaction mixture was heated in a 60 ℃ water bath for 2 hours, and the completion of the reaction of the starting materials was detected by TLC. The reaction mixture was concentrated under reduced pressure, and the residue was extracted with dichloromethane, washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane/ethyl acetate, 50: 1 to 1: 1) to give (R, S) -3-, [ white solid ]³H]-(C³HH₂) Larotrectinib (Compound 6) (4.08g), 92.3% yield, mp 98.2 ℃. TLC: Rf (n-hexane/ethyl acetate, 5/3) ═ 0.32.

Example 4

A control (R, S) -3- (CH3) -Larotrectinib (Compound No. 6) was prepared as in example 3.

The novel compound (R, S) -3-, [ prepared in example 3-4³H]CH₃Laeotercitinib as a novel TRK specific probe can be used for affinity evaluation of tropomyosin receptor kinase (Trk for short) and tyrosine kinase receptors in vivo and in vitro and detection of expression of TRK fusion protein in tumor tissues, thereby providing clinical examinationThe method can be used for reliable diagnosis and molecular phenotype data, and can also be used for in vitro cell receptor and drug molecule screening evaluation.

Example 5

Synthesis of radiofluoro-18-labeled difluoromethoxy-lapatinib (R, S) -3- [18F ] -difluoromethoxy-Larotretinib (12):

the labeled precursor (R, S) -Larotrectinib 6(1.0mg) was dissolved in a V-flask (5mL) containing 400. mu.l of freshly distilled anhydrous tetrahydrofuran, potassium tert-butoxide (1mg) was added to the reaction mixture, and the mixture was allowed to stand for 4 minutes after shaking for 10 seconds. Radioactive [18F ] -difluoromethylbenzenesulfonate ([18F ] FFCHOTos) was pressed dropwise into the reaction mixture with a nitrogen stream, turned at room temperature for 5 minutes, and after the completion of the transfer, the reaction mixture was heated in a 60 ℃ water bath for 20 minutes and then injected directly into a semi-preparative HPLC (Phenomenex C18,10x250 mm,10um, 00G-4094-N0, Phenomenex column of phylum usa) to isolate the product as acetonitrile: 1M ammonium formate solution (65:35, v/v) at a flow rate of 10 ml/min. The precursor Rt peaked at 5-6min, the product Rt peaked at 9-10min, the product was collected based on isotopic γ -detector peak position, diluted with 100uL of deionized water, enriched over C18-solid phase extraction short column (Waters), and eluted with ethanol (1mL) to give (R, S) -3- [18F ] FCFH) -Larotrectinib (21% + -5% yield, EOS). Taking part of the ethanol solution for detection by analytical HPLC, determining that the part of the ethanol solution is taken for detection by analytical HPLC, determining that the radioactivity is more than 2000Ci/mmol (EOS) and the radiochemical purity is more than 99%, and analyzing the conditions as follows: phenomenex c18,10250mm,10ml, eluent acetonitrile: 1M ammonium formate solution (65:35, v/v), flow rate 2ml/min, product peak out time Rt 7.2min, isotope gamma detector determined peak position. The ethanol solution was diluted with physiological saline to obtain a 10% ethanol-saline solution, which was then prepared to contain (R, S) -3- [18F ] FCFH) -Larotrectinib and a final 10% ethanol-saline solution (10 mL).

Preparation of radioactive [18F ] -difluoromethylbenzenesulfonate ([18F ] FFCHOTos) by the method of the reference (Improved synthesis of [18F ] fluoromonomer tosylate, a continuous reagent for radiofluoromonomers, J Label company radiopharmam 2005; 48:557 568) starting with an aqueous [18F ] F-solution, according to the literature procedures, and bis (fluoroxy) fluoromonomers, in high yields in the presence of water. The precursor bis (cosyloxy) fluoromethane, (R, S) -Larotrectinib 6 was purchased commercially or prepared by reference.

Example 6

Synthesis of control non-radioactive F-19 marker (R, S) -3-difluoromethoxy-Larotrectinib (6)

Compound 1(R, S) -3-Larotrectinib (50g,0.226mol,1equiv) was dissolved in 400mL of acetonitrile, cuprous iodide (8.6g, 0.045mol, 0.2equiv) was added, the mixture was heated to 50 ℃, and a solution (100mL) of acetonitrile in which 2-fluorosulfonyl-2, 2-difluoroacetic acid (52.3g, 0.294mol, 1.3equiv) was dissolved was added dropwise to the reaction solution over 45 minutes. The reaction mixture was allowed to continue at 50 ℃ for 30 minutes and TLC checked for complete conversion of starting material. Removing acetonitrile solvent under reduced pressure, dissolving the residue in ethyl acetate, filtering to remove insoluble solid, concentrating ethyl acetate filtrate under reduced pressure to obtain crude product, purifying with silica gel column chromatography (n-hexane/ethyl acetate, 50: 1 to 1: 1) to obtain white solid (R, S) -3- (CF)₂H) Larotrectinib (Compound 6) (3.92g), 82.3% yield, mp 97.6 ℃. TLC: Rf (n-hexane/ethyl acetate, 5/3) ═ 0.41. ESI-MS (m/z): [478.17, M +]。

The novel compound (R, S) -3- ([18/19F ] CF2H) -Laeootretinib prepared in examples 5-6 can be used as a novel TRK specific PET probe for affinity evaluation of tropomyosin receptor kinase (Trk) and tyrosine kinase receptors in vivo and in vitro and for detection of expression of TRK fusion protein in tumor tissues, so that reliable diagnosis and molecular phenotype data can be provided for clinical examination, and the novel compound (R, S) -3- ([18/19F ] CF2H) -Laeotretinib can also be used for screening evaluation of cell receptors and drug molecules in vitro.

Example 7

The radioactive fluorine-18 marker (R, S) -3-, [ 2 ]¹⁸F]-monofluoromethoxy-labeled Latricinib (R, S) -3- (C)¹⁸FH₂) Synthesis of Larotrectinib (12)

The labeled precursor (R, S) -Larotrectinib 6(1.0mg) was dissolved in a V-flask (5mL) containing 400. mu.l of freshly distilled anhydrous tetrahydrofuran, potassium tert-butoxide (1mg) was added to the reaction mixture, and the mixture was allowed to stand for 4 minutes after shaking for 10 seconds. Will emit radioactivity [18F ]]-monofluoromethylbenzenesulfonate ([ 18F)]FCH2OTos) was pressed into the reaction mixture dropwise with a nitrogen stream, turned at room temperature for 5 minutes, and after the completion of the turn-in, the reaction mixture was heated in a 60 ℃ water bath for 2 minutes and then directly injected into a semi-preparative HPLC (Phenomenex C18,10x250 mm,10um, type 00G-4094-N0, Phenomenex chromatography column, usa) to isolate the product, the eluent being acetonitrile: 1M ammonium formate solution (65:35, v/v) at a flow rate of 10 ml/min. Peak at precursor Rt 5-6min, product Rt 9-10min, product collection based on isotopic γ -detector peak position, dilution with 100uL of deionized water, C18-solid phase extraction short column (Waters) enrichment, elution with ethanol (1mL) to give (R, S) -3-, (R, R-y-l, and (R-y-l) in the form of a solid-phase extraction short column (Waters) solution¹⁸F)-CFH₂) Larotrectinib (yield 16%, EOS). Detecting part of ethanol solution with analytical HPLC, determining part of ethanol solution with analytical HPLC, and determining specific activity of radioactivity>2000Ci/mmol (EOS) and radiochemical purity>99%, analysis conditions: phenomenex c18,10250mm,10ml, eluent acetonitrile: 1M ammonium formate solution (65:35, v/v), flow rate 2ml/min, product peak out time Rt 6.9min, isotope gamma detector determined peak position. The ethanol solution was diluted with physiological saline to obtain a 10% ethanol-saline solution, which was then prepared to contain (R, S) -3- (11CH3) -Larotrectinib and a final 10% ethanol-saline solution (10 mL).

[18F]-monofluoromethanesulfonate (¹⁸F]FCH₂OTos), reference (Improved synthesis of [18F ]]fluoromethyl tosylate,a convenient reagent for radiofluoromethylations，J Label Compd Radiopharm 2005; 48: 557-568) method to initiate [18F ]]Aqueous solutions of F-are prepared in high yield according to literature procedures with bis (tosyloxy) methane in the presence of water. The precursor bis (tosyloxy) methane, (R, S) -Larotrectinib 6 was purchased commercially or prepared by reference.

Example 8

Synthesis of control

In a 500mL reactor, 15mg (39.8mmol) of Kryptofix,2.6mg (KF), 11mg (30.9mmol) bis (tosyloxy) methane toluene disulfonate, 250mL acetonitrile were added, the reaction mixture was heated to 110 ℃ for 2 hours, the reaction mixture was cooled to room temperature, the solvent was removed under reduced pressure, the residue was added to dichloromethane (200mL) and well stirred, the mixture was subjected to neutral alumina column chromatography with n-hexane: the mixture of ethyl acetate (95: 5, v/v) was eluted, the organic phases containing the product were combined and concentrated under reduced pressure to give the residue as crude monofluoromethylbenzenesulfonate, which was sampled for TLC and HPLC analysis. TLC showed (2 developed layers, n-hexane: ethyl acetate (4: 1, v/v) Rf0.45 as product monofluoromethylbenzenesulfonate (FCH2OTos) and 0.55 as by-product benzenesulfonyl chloride.

HPLC analysis showed (Alltech econospheree C18, 4.6x 250mM, 5 m.) mobile phase 25mM aqueous ammonia solution: and (3) performing gradient elution by methanol (55: 45-40-60) at a flow rate of 1mL/min for 25min, wherein the peak emergence time Rt of the product monofluoromethyl benzene sulfonate is 10.9min, and the peak emergence time of the byproduct benzene sulfonyl chloride is 14.1 min.

And (3) carrying out silica gel column chromatography on the crude product, and carrying out reaction with n-hexane: eluting with ethyl acetate (95: 5, v/v) mixed solution, collecting product peak eluate, mixing eluates containing product, concentrating under reduced pressure to obtain residue which is monofluoromethyl benzene sulfonate, and detecting by TLC to obtain single fluorescence spot. The purity of the product, namely, the monofluoromethyl benzene sulfonate (FCH2OTos) is more than 99 percent through HPLC detection.

The labeled precursor (R, S) -Larotrectinib 6(10g) was dissolved in a V-shaped reaction flask (50mL) containing 100mL of freshly distilled anhydrous tetrahydrofuran, sodium hydrogen (NaH) (2g) was added to the reaction solution, and the mixture was heated to reflux and stirred for 2 hours. And (3) dropwise pressing the monofluoromethyl benzene sulfonate into the reaction mixture by using nitrogen flow, wherein the transfer time is 15 minutes, after the transfer, heating the reaction mixture in a water bath at 60 ℃ for 2 hours, dropwise adding the mixture into the reaction solution, and after the dropwise adding is finished within 45 minutes. The reaction mixture was allowed to continue at 50 ℃ for 30 minutes and TLC checked for complete conversion of starting material. The tetrahydrofuran solvent was removed under reduced pressure, the residue was dissolved in ethyl acetate, insoluble solids were removed by filtration, and the ethyl acetate filtrate was concentrated under reduced pressure to give a crude product which was purified by silica gel column chromatography (n-hexane/ethyl acetate, 50: 1 to 1: 1) as a residue to give (R, S) -3- (CFH2) -Larotrectinib (Compound 6) (3.92g) as a white solid in 82.3% yield and 89.3 ℃ melting point. TLC: Rf (n-hexane/ethyl acetate, 5/3) ═ 0.38. ESI-MS (m/z): [459.19, M + ].

The radioactive fluorine-18 marker (R, S) -3- [18F ] -monofluoromethoxy-labeled lapatinib (R, S) -3- (C18FH2) -larostrininb (12) prepared in examples 7 to 8 is used as a novel TRK-specific PET probe, can be used for affinity assessment of Tropomyosin Receptor Kinase (TRK), a type of tyrosine kinase receptor, and detection of expression of TRK fusion protein in tumor tissue, thereby providing reliable diagnosis and molecular phenotype data for clinical examination, and can also be used for screening and assessing in vitro cell receptors and drug molecules.

Example 9

Radioactive fluorine-18 marker (R, S) -3- [18F]F-d 2-monofluoromethoxy-lapatinib (R, S) -3-d2- (C)¹⁸FD₂) -synthesis of Larotrectinib (12);

[¹⁸F]f-d 2-methoxy-Larotrectinib

[18F]The F-d2-MT reference (Beyerlein, F.; Piel, M.;

S.；

labelled compound.radiopharm.2013, 56,360) to start [18 f.](ii) an aqueous solution of F- (6-7GBq) [18F ] synthesized according to the literature]F-d2-MT([18F]fluoro-d2-methyl tosylate([18F]F-d2-MTos) was purified by semi-preparative HPLC and Strata^TMEnrichment on an X SPE solid phase extraction cartridge (Phenomenex, Philomenex USA) and drying with helium, eluting the adsorbed [18F ] with DMSO (0.7mL) solvent]F-d2-MT to a V-type reactor to obtain (1.9-2.7GBq) [18F]F-d2-MT (radiochemical purity greater than 98%).

After heating to 120 ℃ the mixture was transferred to a reactor containing the precursor (3mg), NaOH (5.6uL, 5N) and DMSO (0.3mL) and reacted at 110 ℃ for 20 min. After cooling to 55 deg.C, the collected radioactive product was diluted by addition of a mixed eluent of acetonitrile and 50mM ammonium formate (65:35, v/v) (1mL), and diluted by addition of water (25mL) and then injected directly into a semi-preparative HPLC (Phenomenex C18,10X250 mM,10um, 00G-4094-N0, Phnomenex column, USA) to isolate the product, the eluent being acetonitrile: 1M ammonium formate solution (65:35, v/v) at a flow rate of 10 ml/min. The precursor Rt ═ 5-6min peaked, the product Rt ═ 9-10min, the product was collected based on the isotopic γ -detector peak position, diluted with 100uL of deionized water, enriched by C18-solid phase extraction short column (Waters), rinsed with water (10mL), dried with a helium stream, and eluted with ethanol (1mL) to give (R, S) -3 [, ]¹⁸F]F-d 2-Laeottutinib. Detecting part of ethanol solution with analytical HPLC, determining part of ethanol solution with analytical HPLC, and determining specific activity of radioactivity>2000Ci/mmol (EOS) and radiochemical purity>99%, analysis conditions: phenomenex C18,10X250 mm,10um, eluent acetonitrile: 1M ammonium formate solution (65:35, v/v), flow rate 2ml/min, product peak out time Rt 6.9min, isotope gamma detector determined peak position. Diluting the ethanol solution with normal saline, and preparing into final product containing (R, S) -3-, [ 2 ], [ 10% ethanol-normal saline solution¹⁸F]10% ethanol-physiological saline solution (10mL) (0.8-1.2GBq) of F-d 2-monofluoromethoxy-Larotretinoib product, total radiochemical yield approximately 35+ -5% and radiochemical purity greater than 97%.

Example 10

Synthesis of control

(R, S) -3-d 2-monofluoromethoxy-Larotrectinib product

Under nitrogen protection, the labeled precursor (R, S) -Laeotteptiib 6(4.28g, 0.1mol) (428.4mg,1mmol) was dissolved in a flame-dried magnetically stirred reaction flask (50mL) containing freshly distilled anhydrous acetonitrile (35mL), potassium tert-butoxide (1.34mg, 0.12mol) (112.2mg,1mmol) was added in one portion to the reaction mixture, and the reaction was stirred at room temperature for 15 minutes. 137ul (1mmol) of (d 2-monofluoromethyl p-toluenesulfonate) (d 2-CFD)₂Tos) (1.36mL,1.45g/mL, 0.12mol) was added dropwise to the reaction mixture over a 15 minute period, the addition was complete, the reaction mixture was stirred at room temperature for 2 hours, a solution of TBAF (1M, 4mL) in tetrahydrofuran was added to the reaction mixture, the solution appeared brown-yellow and the reaction was continued for 18 hours at room temperature, and TLC followed complete conversion of the starting material. The reaction mixture was concentrated under reduced pressure, and the residue was extracted with dichloromethane, washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane/ethyl acetate, 50: 1 to 1: 1) to give (R, S) -3-d 2-monofluoromethoxy-larotrytinib product (compound 6) (134.96mg) as a white solid with a yield of 29.2% and a melting point of 97.3 ℃. TLC: Rf (n-hexane/ethyl acetate, 5/3) ═ 0.29. ESI-MS (m/z): [462.2, M +]

The precursor d 2-monofluoromethyl p-toluenesulfonate, (R, S) -Larotrectinib 6 was purchased commercially or prepared by reference.

Radioactive fluorine-18 marker (R, S) -3- [ 18F) prepared in examples 9 to 10]F-d 2-monofluoromethoxy-lapatinib (R, S) -3-d2- (C)¹⁸FD₂) Larotrectinib (12) as a novel TRK specific PET probe can be used for affinity evaluation of tropomyosin receptor kinase (Trk), a class of tyrosine kinase receptors in vivo and in vitro, and detection of expression of TRK fusion protein in tumor tissues, so as to detect the presence of TRK fusion protein in tumor tissuesBed examination provides reliable diagnostic and molecular phenotypic data, and can also be used for in vitro cell receptor and drug molecule screening evaluation.

Example 11

Radioactive (R, S) -3- (2-, [ 2 ]¹⁸F]fluoroethyl-O)-Larotrectinib((R，S)-3-(2-[¹⁸F]Fluoroethoxy) latsatinib) synthesis

2-[¹⁸F]Fluoroethyl p-toluenesulfonate ([ 18F)]The FETos references (Beyerlein, F.; Piel, M.;

S.；

labelled compound.radiopharm.2013, 56,360) to start [18 f.]2- [18F ] 2- [ 6-7GBq ] aqueous solution synthesized according to the literature]Fluoroethyl p-toluenesulfonate ([ 18F)]FETos were purified by semi-preparative HPLC separation and enriched on a StrataTM X SPE solid phase extraction cartridge (Phenomenex, Philomena, USA) and dried with helium, and the adsorbed 2- [18F ] eluted with DMSO (0.8mL) solvent]Fluoroethyl p-toluenesulfonate ([ 18F)]FETos to type V reactor to obtain (1.9-2.7GBq)2- [18F]Fluoroethyl p-toluenesulfonate ([ 18F)]FETos (radiochemical purity greater than 98%).

After heating the V-shaped reactor to 130 ℃ the mixture was transferred to a reactor containing the precursor (3mg, 15. mu. mol), NaOH (5.6uL, 5N) and DMSO (0.3mL) and reacted at 130 ℃ for 10 min. After cooling to 55 ℃ a mixed eluent of acetonitrile and 50mM ammonium formate (65:35, v/v) (1mL) was added for dilution and then injected directly into a semi-preparative HPLC (Phenomenex C18,10X250 mM,10um, 00G-4094-N0, Phnomenex column, USA) to isolate the product as acetonitrile: 1M ammonium formate solution (65:35, v/v) at a flow rate of 10 ml/min. The precursor Rt is 5-6min out of the peak, the product Rt is 9-10min, the product is collected based on the peak position of an isotope gamma-detector, deionized water (25mL) is added to dilute the collected radioactive product, and the radioactive product is enriched to a solid phaseExtract (Strata)^TMX SPE cartridge, Phenomenex, Philomenax, USA Philomo, after washing with water (10mL), helium is dried, and then ethanol (2mL) is used for elution to obtain (R, S) -3- (2-, [ solution of sodium hydrogen carbonate and sodium hydrogen carbonate ])¹⁸F]fluoroethyl-O)-Larotrectinib((R，S)-3-(2-[¹⁸F]Fluoroethoxy) latsatinib). Detecting part of ethanol solution with analytical HPLC, determining part of ethanol solution with analytical HPLC, and determining specific activity of radioactivity>2000Ci/mmol (EOS) and radiochemical purity>99%, analysis conditions: phenomenex C18,10X250 mm,10um, eluent acetonitrile: 1M ammonium formate solution (65:35, v/v), flow rate 2ml/min, product peak out time Rt 6.9min, isotope gamma detector determined peak position. Diluting the ethanol solution with normal saline to obtain 10% ethanol-normal saline solution, and preparing into final product containing (R, S) -3- (2-, [ 2- ]¹⁸F]fluoroethyl-O)-Larotrectinib((R，S)-3-(2-[¹⁸F]Fluoroethoxy) lapatinib) product in 10% ethanol-saline solution (10mL) (0.8-1.2GBq) for a total radiochemical synthesis time of 110 minutes, a total radiochemical yield of approximately 47+ -3% and a radiochemical purity of greater than 97%.

Example 12

Synthesis of reference 2-fluoroethyl-O-Larotretinib (2-fluoroethoxyl lapatinib)

(R, S) -Larotrectinib (100mg,0.5mmol), dry ethanol (10mL), and potassium carbonate (97mg, 0.7mmol) were charged into a reactor, and after stirring at room temperature for 15 minutes, a dry ethanol solution (5mL) of 2-fluoroethyl p-toluenesulfonate (87.2mg, 0.5mmol) was added, and the reaction mixture was heated to 70 ℃ and reacted for 18 hours. TLC checked complete conversion of starting material, evaporated ethanol and the crude product was chromatographed on silica gel using a mixed solvent as eluent (DCM: MeCH3: TEA ═ 10:1:0.002) to give 56mg (0.23mmol, 46%) of a pale yellow solid.

1H NMR(300MHz,CDCl3)d[ppm]＝11.434(s 1H),8.152(d,1H),8.077(d,1H),7.813(d,1H),7.026(d,1H),6.88(dd,1H),4.885(t,1H),4.726(t,1H),4.393(t,1H),4.292(t,1H),2.712(s,3H).

ESI-MS(ESI+):m/z:475.20([M+1]+).

The invention develops a novel TRK PET probe, which has TRK specificity, and has the functions of realizing the visualization and quantitative evaluation of the physiological and biochemical functions and the pharmacological process of the drug molecules on the level of molecules in vivo by means of a PET (Positron emission tomogry) non-immersion imaging technology. The invention modifies the existing small molecular compound aiming at the Trk fusion protein, thereby further forming a molecular probe capable of specifically diagnosing Trk fusion protein expression, serving as a small molecular inhibitor of Tropomyosin Receptor Kinase (TRK), having strong selectivity on TRK, being used as a PET imaging molecule, accurately positioning the Larotrectinib molecule in vivo to evaluate the tumor condition, realizing the on-line tracing of the distribution of the Larotrectinib molecule in animals or human bodies and the condition of solid tumors, intuitively judging the physiological function and pharmacological process of the Larotrectinib in animals, human bodies and tumors, judging the curative effect and the effect after healing, and enhancing the concentration effect of the Larotrectinib in the tumors. Thereby providing reliable molecular typing data for clinically carrying out molecular diagnosis on the characteristics of the tumor and guiding the clinical medication of related Trk fusion protein. Can also be used for in vitro cell receptor and drug molecule screening and evaluation.

The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.

Claims (8)

1. An alkoxy-substituted lapatinib compound comprising lapatinib labeled with radioactive atoms or non-radioactive atoms, wherein the radioactive atoms include 11C, 3H, 18F and the non-radioactive atoms include 12C, 2H, 19F.

2. The alkoxy-substituted lapatinib compound according to claim 1, wherein the compound has the following general structural formula:

wherein R is:^11/12CH₃-，C^1/2/3H₃-，C^18/19F^1/2/3H₂-，C^18/19F₂ ^1/2/3H-，(CH₂)_n ^18/19F-、CH₂(CH₂-O-CH₂CH₂)n^18/19F-，CH₂CH^18/19FCH₂OH-, cycloalkyl, or radiolabeled cycloalkyl [ CH₂(CHCH₂CH)CH₂C^{18 /19}F^1/2/3H₂-]。

3. The alkoxy-substituted latsatinib compound according to claim 1 or 2, characterized in that the compound is a radioactive-like compound¹¹The C-methoxy labeled Latrotinib compound has a structural formula comprising:

4. the alkoxy-substituted latsatinib compound according to claim 1 or 2, characterized in that the compound is a radioactive-like compound³The structural formula of the H-methoxy labeled Latrotinib compound comprises:

5. the alkoxy-substituted latsatinib compound according to claim 1 or 2, characterized in that the compound is a radioactive-like compound¹⁸The structural formula of the F-methoxy labeled Latrotinib compound comprises:

6. the alkoxy-substituted latsatinib compound according to claim 1 or 2, characterized in that the compound is non-radioactive like¹H-、²H-、¹⁹An F-labeled Latricinib compound, the structural formula comprises:

7. a process for the preparation of an alkoxy substituted lapatinib compound according to claim 1 or 2, wherein the compound is prepared by:

8. use of an alkoxy substituted latsatinib compound according to claim 1 or 2 as medicament for the clinical and preclinical diagnosis and evaluation of the therapeutic efficacy of diseases which are caused by tropomyosin kinase TRK fusion proteins.